J Patient Exp
January 2025
Patient experience is a vital measure of healthcare quality, affecting satisfaction, engagement, and outcomes. Standardized radiology reporting can improve care by enhancing communication, reducing errors, and optimizing workflows. This article examines the role of structured reporting and AI in improving patient experience, addressing challenges like workload imbalances and communication issues.
View Article and Find Full Text PDFThe digitization of aircraft cockpits places high demands on the colour vision of pilots. The present study investigates colour vision changes upon acute exposure to hypobaric hypoxia. The digital Waggoner Computerized Color Vision Test and the Waggoner D-15 were performed by 54 healthy volunteers in a decompression chamber.
View Article and Find Full Text PDFThe aim of this study was to investigate the representation of women in the German-speaking scientific publication landscape of otorhinolaryngology.Authorship was analyzed based on articles published between 2013 and 2023 in the two largest otorhinolaryngology journals (Laryngorhinootologie, HNO) to determine the frequency and percentage of gender distribution among first and last authorships.A total of 2,631 articles were examined.
View Article and Find Full Text PDFBackground: Orexin neuropeptides help regulate sleep/wake states, respiration, and pain. However, their potential role in regulating breathing, particularly in perioperative settings, is not well understood. TAK-925 (danavorexton), a novel, orexin receptor 2-selective agonist, directly activates neurons associated with respiratory control in the brain and improves respiratory parameters in rodents undergoing fentanyl-induced sedation.
View Article and Find Full Text PDFIntroduction: Because booster doses of pneumococcal conjugate vaccine (PCV) may be given at a similar time to yellow fever vaccine (YF), it is important to assess the immune response to YF when co-administered with PCV. This has been investigated during a reduced-dose PCV trial in The Gambia.
Methods: In this phase 4, parallel-group, cluster-randomized trial, healthy infants aged 0-10 weeks were randomly allocated to receive either a two-dose schedule of PCV13 with a booster dose co-administered with YF vaccine at age 9 months (1 + 1 co-administration) or YF vaccine administered separately at age 10 months (1 + 1 separate) or the standard three early doses of PCV13 with YF vaccine at age 9 months (3 + 0 separate).